Ingredient giant Ingredion has forged a strategic R&D collaboration with Shiru, an artificial intelligence (AI)-driven protein discovery platform, aiming to accelerate the commercialization of novel prebiotics designed to capitalize on the burgeoning interest in gut health, particularly as influenced by the widespread adoption of GLP-1 medications. This partnership, announced amidst a landscape where protein, fiber, AI, and gut health are at the forefront of food technology innovation, signifies a concerted effort to unlock new possibilities in functional ingredients for the food, beverage, supplement, and specialized nutrition sectors.
The immediate focus of this collaboration is the development of "next-generation" natural prebiotics, engineered to promote healthier gut microbiomes. The companies assert that AI-driven protein discovery offers a unique advantage, enabling access to novel ingredient functionalities that are often beyond the reach of conventional research and development methods. This technological synergy is poised to address the increasing consumer demand for advanced health solutions and the corresponding need for food companies to innovate at an accelerated pace.
Michael Leonard, Chief Innovation Officer at Ingredion, articulated the strategic imperative behind the partnership: "As consumer expectations rise, food companies need new ways to move faster and innovate smarter. Shiru helps us discover better natural ingredients more quickly so we can help our customers deliver new products at a pace the market expects." This sentiment underscores the industry’s drive to adapt to evolving consumer priorities and leverage cutting-edge technology to meet market demands efficiently.
Shiru’s AI-powered platform, Flourish, is central to this initiative. The platform meticulously catalogs and analyzes the performance characteristics of an immense database, reportedly encompassing 77 million unique, naturally occurring proteins. This extensive data set allows for the rapid identification of proteins with specific functional properties, a crucial step in developing targeted nutritional solutions. Furthermore, Shiru operates ProteinDiscovery.ai, a publicly accessible marketplace that serves as the world’s most extensive repository of plant-derived and microbial proteins. This platform empowers corporate partners to swiftly identify and evaluate highly functional, natural ingredients, thereby streamlining the innovation pipeline.
Jasmin Hume, Founder and CEO of Shiru, highlighted the transformative nature of their technology: "We have broken the mold on how ingredient discovery is done. Disrupting the speed at which we can identify high-performance natural proteins has opened the floodgates for healthy, targeted nutrition. What once took a team of 50 scientists a decade and a healthy dose of serendipity, we can now do strategically and efficiently in months. Pairing that capability with Ingredion’s scale and customer relationships creates a direct path from discovery to market." This statement emphasizes the significant leap in efficiency and strategic targeting that AI brings to ingredient development, bridging the gap between scientific discovery and commercial viability.
The joint R&D program between Ingredion and Shiru is designed to leverage Shiru’s AI capabilities to create innovative ingredients for the rapidly expanding gut health market. The resulting ingredients will have a direct route to Ingredion’s extensive customer base, which comprises over 18,000 clients across 120 countries, ensuring broad market penetration and impact. The strategic focus on gut health is informed by a growing body of scientific evidence linking microbiome health to enhanced immunity, improved metabolic function, and optimized cognitive performance. Consequently, consumer packaged goods (CPG) companies are increasingly motivated to reformulate their products with ingredients that possess clinical credibility and can be produced at scale.
The Gut Health Revolution: A Confluence of Wellness Trends and Pharmaceutical Advancements
The timing of this partnership is particularly significant, as gut health has emerged as a paramount wellness priority for a substantial segment of the population. In the United States, for instance, 37% of Americans identified gut health as a top wellness focus in recent surveys. This heightened consumer interest has been fueled by a confluence of factors, including popular documentaries such as Netflix’s "Hack Your Health," the proliferation of personalized nutrition applications like Zoe, and widespread online trends like "fibermaxxing" and "fibrelayering" popularized on social media platforms.
Crucially, the rise in awareness and adoption of Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic and Mounjaro, has significantly amplified the focus on gut health and its role in metabolic regulation and weight management. Between early 2024 and the summer of 2025, the percentage of Americans utilizing these weight-loss medications more than doubled, escalating from 5.8% to 12.4%. These medications function by mimicking incretin hormones naturally present in the body, which play a vital role in regulating blood sugar, promoting satiety, and aiding in weight management.
The food industry is actively seeking to harness these physiological mechanisms through natural dietary interventions. Dietary fibers and prebiotics, in particular, are recognized for their ability to feed beneficial gut bacteria, which in turn produce short-chain fatty acids (SCFAs). SCFAs are known to stimulate the release of GLP-1 from intestinal cells, thereby mimicking some of the effects of GLP-1 medications. This burgeoning understanding has led to a surge in innovative food and beverage products designed to support gut health and metabolic well-being. A prime example of this trend is the proliferation of prebiotic sodas from brands like Olipop and Poppi, whose market success prompted major beverage corporations like PepsiCo to acquire Poppi and Coca-Cola to launch its own versions.
Shiru has proactively positioned itself within this evolving landscape. The company is a founding member of the GLP-1 Innovation Alliance, an initiative aimed at fostering collaboration between food industry giants and emerging startups to explore natural approaches to activating GLP-1 pathways. This strategic engagement underscores Shiru’s commitment to being at the forefront of natural solutions for metabolic health.
Ingredion and Shiru: A Synergistic Approach to Ingredient Innovation
Ingredion, a global leader in ingredient solutions, brings unparalleled market reach and deep customer relationships to this partnership. With a portfolio spanning diverse industries, Ingredion is well-positioned to integrate novel ingredients developed through the collaboration into a vast array of consumer products. Their expertise in ingredient science, application development, and global supply chain management will be critical in scaling production and ensuring the widespread availability of these next-generation prebiotics.
Shiru, having raised $36 million in funding, has a proven track record in AI-driven ingredient discovery and commercialization. The company has previously brought to market uPro, a plant-based blend designed to replicate animal fats for applications in plant-based meat, dairy, and cosmetics. Additionally, OleoPro, a structured fat alternative derived from unsaturated oils and uPro, has also been commercialized. Shiru is also collaborating with GreenLab, a plant biotech platform, to develop novel food proteins for CPG applications using GreenLab’s corn expression system. These past successes demonstrate Shiru’s capability to translate AI-generated discoveries into commercially viable ingredients.
The strategic alignment between Ingredion and Shiru is further reinforced by the broader industry trend of leveraging AI for natural GLP-1 activation. Companies such as NotCo in Chile are employing AI to develop botanical powders that act as natural GLP-1 boosters, positioning themselves as alternatives to pharmaceutical interventions. Similarly, Lembas has developed a bioactive peptide designed to stimulate the body’s natural GLP-1 response. This competitive yet collaborative environment highlights the significant market opportunity and the growing recognition of AI’s role in developing sustainable and health-focused food solutions.
Implications and Future Outlook
The partnership between Ingredion and Shiru is poised to have significant implications for the food industry and consumer health. By combining Ingredion’s global scale and market access with Shiru’s cutting-edge AI discovery platform, the collaboration is set to accelerate the development and commercialization of novel prebiotic ingredients. These ingredients have the potential to address a wide range of health concerns, from improving gut microbiome diversity and function to supporting metabolic health and weight management, aligning with the growing consumer demand for scientifically backed, natural health solutions.
The focus on next-generation prebiotics is particularly timely, given the increasing understanding of the intricate relationship between the gut microbiome and overall health. As research continues to unravel the complexities of gut health, the demand for functional ingredients that can modulate the microbiome and deliver targeted health benefits is expected to grow exponentially. This partnership is strategically positioned to meet this demand, offering innovative solutions that cater to the evolving needs of consumers and the food industry alike.
The success of this venture could pave the way for further AI-driven innovations in ingredient discovery, not only within the gut health space but also across other critical areas of nutrition and health. The ability to rapidly identify and develop novel, high-performance natural ingredients at scale represents a paradigm shift in food technology, promising a future where personalized nutrition and scientifically validated health benefits are more accessible than ever before. The collaborative effort between Ingredion and Shiru stands as a testament to the transformative power of AI in addressing complex global health challenges and shaping the future of food.